CN113832113B - Novel duck reovirus attenuated strain and application thereof - Google Patents

Novel duck reovirus attenuated strain and application thereof Download PDF

Info

Publication number
CN113832113B
CN113832113B CN202111076984.8A CN202111076984A CN113832113B CN 113832113 B CN113832113 B CN 113832113B CN 202111076984 A CN202111076984 A CN 202111076984A CN 113832113 B CN113832113 B CN 113832113B
Authority
CN
China
Prior art keywords
ser
ala
leu
duck reovirus
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111076984.8A
Other languages
Chinese (zh)
Other versions
CN113832113A (en
Inventor
李泽君
李雪松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Veteromaru Research Institute Caas China Animal Health And Epidemiology Center Shanghan Branch Center
Original Assignee
Shanghai Veteromaru Research Institute Caas China Animal Health And Epidemiology Center Shanghan Branch Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Veteromaru Research Institute Caas China Animal Health And Epidemiology Center Shanghan Branch Center filed Critical Shanghai Veteromaru Research Institute Caas China Animal Health And Epidemiology Center Shanghan Branch Center
Priority to CN202111076984.8A priority Critical patent/CN113832113B/en
Publication of CN113832113A publication Critical patent/CN113832113A/en
Application granted granted Critical
Publication of CN113832113B publication Critical patent/CN113832113B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses a novel duck reovirus attenuated strain which has sigma C structural protein with an amino acid sequence shown as SEQ ID NO. 1. The invention also discloses a vaccine comprising the novel duck reovirus attenuated strain. The invention also discloses application of the novel duck reovirus attenuated strain in preparation of a product for preventing novel duck reovirus diseases. The novel duck reovirus attenuated strain prepared by the method has the advantages that after 1-day-old healthy susceptible duckling is immunized, the protection rate of the novel duck reovirus attenuated strain on virulent attack reaches 100%, the novel duck reovirus attenuated strain has good safety and effectiveness, and the novel duck reovirus attenuated strain does not generate virulence back after artificial passage in the susceptible duckling, so that the novel duck reovirus attenuated strain has a very good application prospect in preventing and treating the novel duck reovirus of the duckling.

Description

Novel duck reovirus attenuated strain and application thereof
Technical Field
The invention belongs to the technical field of veterinary biological products, and particularly relates to a novel duck reovirus attenuated strain and application thereof as a novel duck reovirus live vaccine.
Background
The disease caused by the novel duck reovirus (Novel duck reovirus, NDRV) infection is a duck viral infectious disease which is mainly characterized by spleen irregular bleeding, swelling, necrosis and the like. The virus is separated from waterfowl such as geese, muscovy ducks, cherry valley ducks, sheldrake and the like, the NDRV can infect duckling of different varieties, the host range of infection is wider than that of typical Muscovy duck reovirus (Muscovy duck reovirus, MDRV), and the pathogenicity and clinical pathological changes caused by the two viruses are also quite different. Since 2017, the morbidity and mortality of novel duck reovirus diseases are gradually increased, and the novel duck reovirus diseases become one of important viral infectious diseases affecting the duck raising industry in China.
NDRV can infect and cause morbidity in muscovy ducks, semi-muscovy ducks, cherry valley ducks, sheldrake and geese, and the like. The virus has serious harm to duckling, the age of the muscovy duck and the half muscovy duck in the onset period is mainly 6-25 days, wherein the age of 7 days is the most, and the course of the disease is 5-7 days; the age of cherry valley ducks in the onset day is mainly 10-30 days. The incidence rate of the novel reovirus is 5-30%, and the death rate is 4-20%.
Vaccination is one of the keys to prevent novel duck reovirus disease. The current vaccines for preventing the disease comprise an inactivated vaccine and a attenuated live vaccine, wherein the inactivated vaccine has slower immunity generation time, usually needs multiple times of immunity to achieve better protection effect, and has weaker cell-mediated immunity, while the attenuated live vaccine has the effect of stimulating the organism to generate comprehensive immune response, has quicker immunity effect generation time and can generate enough protection effect once. Therefore, the novel duck reovirus attenuated live vaccine has more advantages in clinical application compared with the inactivated vaccine in the aspect of protecting duckling.
Disclosure of Invention
The invention aims to solve the technical problem that no novel duck reovirus attenuated live vaccine is clinically effective in preventing the novel duck reovirus disease, and provides a novel duck reovirus attenuated strain, and the novel duck reovirus live vaccine prepared by the attenuated strain can be used for effectively preventing the novel duck reovirus disease.
In order to solve the technical problems, the invention is realized by the following technical scheme:
the invention provides a novel duck reovirus attenuated strain, which has sigma C structural protein with an amino acid sequence shown as SEQ ID NO. 1.
Preferably, the attenuated strain of virus further comprises a sigma a structural protein having the amino acid sequence shown in SEQ ID No. 2.
Preferably, the attenuated strain of virus further comprises a sigma B structural protein having the amino acid sequence shown in SEQ ID NO. 3.
The invention provides a novel duck reovirus attenuated strain JS01-105P, the preservation number of which is CCTCC NO: v202168.
The invention also provides a nucleic acid encoding a structural protein or fragment thereof of:
a sigma C structural protein of the amino acid sequence shown in SEQ ID NO. 1;
or a sigma A structural protein of the amino acid sequence shown in SEQ ID NO. 2;
or a sigma B structural protein of the amino acid sequence shown in SEQ ID NO. 3.
Preferably, the nucleic acid is selected from:
the nucleotide sequence of the sigma C structural protein shown in SEQ ID NO. 4;
or the nucleotide sequence of the sigma A structural protein shown in SEQ ID NO. 5;
or the nucleotide sequence of the sigma B structural protein shown in SEQ ID NO. 6.
The invention also provides a vaccine containing the novel duck reovirus attenuated strain.
The vaccine has good safety and effectiveness to duckling, and the virus content of each feather is not less than 10 3.5 TCID 50
The invention also provides application of the novel duck reovirus attenuated strain in preparation of a product for preventing novel duck reovirus diseases.
The novel duck reovirus attenuated strain JS01-105P provided by the invention is used as a live vaccine for the novel duck reovirus disease, has good safety and effectiveness, and has a protection rate of 100% on virulent attack after 1 day of immunization on healthy and susceptible duckling, and has a very good application prospect on prevention and treatment of the novel duck reovirus disease of the duckling, wherein virulence return does not occur in the susceptible duckling after artificial passage.
Drawings
The invention will be described in further detail with reference to the drawings and the detailed description.
FIG. 1 is a diagram showing the survival rate of the NDRV JS01 strain virulent strain and the inoculated ducks with the virulent strain and the virulent strain after passage in example 2 of the invention;
FIG. 2 is a chart showing the virus titer of the viscera of 1 day old ducks inoculated with the NDRV JS01 strain virulent strain and the passaging strain of the invention in example 2;
FIG. 3 is a schematic diagram of the final product of the novel reovirus attenuated live vaccine of example 4 of the present invention.
The preferred novel duck reovirus attenuated strain is preserved in China center for type culture collection (CCTCC for short, address: university of Wuchang mountain and Wuhan collection in Wuhan, jua, hubei province) at the 1 st month of 2021, and the preservation number is CCTCC NO: v202168, which is classified and named as a novel duck reovirus attenuated strain JS01-105P.
Detailed Description
In order to develop a safe and effective novel duck reovirus attenuated live vaccine, the invention separates and identifies a novel duck reovirus attenuated strain JS01, and continuously passaging and purifying and culturing the novel duck reovirus attenuated strain JS01-105P on SPF chick embryos until 105 generations are obtained. The novel duck reovirus attenuated strain (JS 01-105P) is used as a live vaccine for immunizing 1-day-old healthy susceptible duckling, has good safety and effectiveness, and does not generate virulence return after artificial passage in the susceptible duckling, so that the novel duck reovirus attenuated strain has very good application prospect in the aspect of preventing and treating novel duck reovirus diseases of duckling
Example 1 cultivation and sequence analysis of novel attenuated reovirus vaccine strains
A novel duck reovirus is isolated and identified from cases causing spleen necrosis symptoms of duckling, named as a novel duck reovirus JS01 strain, and inoculated into 9-10-day-old SPF chick embryos by allantoic cavities for continuous culture in an incubator. Discarding dead chick embryo within 24 hours after inoculation, taking out the rest chick embryo once within 24 hours, taking out the dead chick embryo within 2-6 days, preserving at below-15 ℃, melting at room temperature, grinding, collecting supernatant, centrifuging at 3000 r/min for 10 minutes, and packaging the supernatant. Serial subculture was then carried out in the same manner to 100 generations, followed by purification by limiting dilution for 5 times to 105 generations. Full gene sequencing of JS01 and 105-generation viruses shows that compared with JS01, the 105-generation viruses are passaged to amino acid mutation sites of main structural proteins sigma C, sigma A and sigma B of the 105-generation viruses, and have 4 differences in total. Of the 5 amino acid mutations, the sigma C (sigma C) protein has 1 mutation point (T120P), the sigma A (sigma A) protein has 2 mutation points (T44P, E120G), and the sigma B (sigma B) protein has 1 mutation point (L260F). The JS01-105P strain structural protein sigma C has an amino acid sequence shown in SEQ ID NO.1 and a nucleotide sequence shown in SEQ ID NO. 4; the amino acid sequence of the structural protein sigma A is shown as SEQ ID NO.2, and the nucleotide sequence is shown as SEQ ID NO. 5; the amino acid sequence of the structural protein sigma B is shown as SEQ ID NO.3, and the nucleotide sequence is shown as SEQ ID NO. 6.
Example 2 evaluation of pathogenicity of NDRV JS01 strain passage toxin on 1 day old duckling
In order to evaluate the virus pathogenicity change conditions of the 5 th generation (5P), the 75 th generation (75P) and the 105 th generation (105P) of the NDRV JS01 strain, animal experiments are carried out after the purchased SPF duck embryos are hatched to 1 day old, 40 susceptible duckling are randomly divided into 4 groups, 10 duckling groups are respectively arranged in the 1 st group, the NDRV JS01-5P group, the 2nd group is the NDRV JS01-75P group, the 3 rd group is the NDRV JS01-105P group, and the 4 th group is the PBS control group. The 1 st to 3 rd groups of ducklings with 1 day age are subjected to leg intramuscular injection for virus passage, and the virus dosage is 10 5.0 TCID 50 0.1mL, each 0.1mL. Group 4 is a blank control group, and is injected with 0.1mLPBS buffer solution at the legs, continuously observed for 14 days, and observed whether the inoculated duck has clinical symptoms caused by viruses or whether the inoculated duck has local and systemic adverse reactions caused by inoculation.
Organ virus isolation assay: after the purchased SPF duck embryo is hatched to 1 day old, animal experiments are carried out, 40 duckling are randomly divided into 4 groups, 10 duckling groups are respectively, the 1 group is an NDRV JS01-5P generation virus group, the 2 group is an NDRV JS01-75P generation virus group, the 3 group is an NDRV JS01-105P generation virus group, and the 4 group is a PBS control group. Leg injection for passaging virus of 1 day-old duckling of groups 1-3, and virus dose of 10 5.0 TCID 50 0.1mL, each 0.1mL. Group 4 is a blank control group, and was injected with 0.1ml pbs buffer on each leg. 4 days after virus inoculation, all duckling are dissected and killed, and the dissected and the content of the virus in the viscera is measured, wherein the collected viscera comprise heart, liver, spleen, kidney, duodenum, brain, bursa of Fabricius and other viscera tissues.
Results:
clinical symptoms and mortality conditions within 14 days after infection of 1-day-old ducklings by different NDRV JS01 strains: after the muscle is inoculated with the NDRV JS01-5P strain to be virulent, two ducklings die within 14 days, the survival rate is 80%, the ducklings are not dead after the NDRV JS01-75P strain and the NDRV JS01-105P strain are inoculated, and the survival rate is 100% (shown in figure 1). The 3 days after the virus attack, the duckling of the inoculation group of the NDRV JS01-5P strain has symptoms of listlessness, reduced feed intake, diarrhea and the like; the young ducks of the NDRV JS01-75P strain inoculation group have diarrhea symptoms; NDRV JS01-105P vaccinations and PBS vaccinations had no adverse clinical symptoms.
Different NDRV JS01 strains are inoculated to ducklings of 1 day old after being subjected to virus passage, killing is carried out after 4 days, and pathological observation is shown as a figure 2, wherein the livers of the ducklings inoculated with NDRV JS01-5P show serious bleeding points, and the livers of the ducklings of 75P, 105P and the control group have no obvious change; the spleen of the NDRV JS01-5P inoculated duck has severe bleeding, swelling and necrosis, the spleen of the passaged virus 75P inoculated duck has bleeding, slight swelling and dead spots, and the spleen of the 105P and the spleen of the control duck have no obvious change. The NDRV JS01 strain is virulent and passaged to inoculate 1-day-old healthy susceptible duckling, the duckling is dissected and killed after 4 days, each group is used for taking heart, liver, spleen, lung, kidney, duodenum, bursa and brain of inoculated duckling to perform virus titration, NDRV sensitive LMH cells are used for titration, and the result of the viscera virus titration of the NDRV JS01-5P and passaged virus (75P and 105P) inoculated duckling is shown in figure 2. After the NDRV JS01-5P infects ducks, viruses can be detected in heart, liver, spleen, lung, kidney, duodenum, bursa of Fabricius and brain, and systemic infection is presented, wherein the content of the viruses in the lung, spleen, lung and kidney is highest; NDRV JS01-75P vaccinated ducks mainly infect spleen and bursa of Fabricius; the NDRV JS01 strain passaging virus 105P inoculated duck can only detect low-content virus in the spleen of part of ducks.
EXAMPLE 3 minimum immune dose study of novel reovirus JS01-105P strain
To determine the optimal immunization dose of NDRV JS01 strain attenuated strain JS-105P on 1-day-old ducklings: animal experiments were performed after incubating purchased SPF duck embryos to 1 day of age, and 40 healthy susceptible ducklings were randomly divided into 4 groups of 10 ducklings each. Group 1: leg muscle inoculation NDRV JS01-105P with dosage of 10 2.0 TCID 50 Each 0.1mL; group 2: leg muscle inoculation NDRV JS01-105P with dosage of 10 2.5 TCID 50 Each 0.1mL; group 3: leg muscle inoculation NDRV JS01-105P with dosage of 10 3.0 TCID 50 Each 0.1mL; group 4: PBS control group, leg muscle inoculated with PBS, each 0.1mL. When duckling is 7 days old (i.e. 6 days after immunization), all 4 groups of duckling are subjected to virus elimination and muscle inoculation is carried out for 10 days 5.0 TCID 50 The NDRV JS01 is virulent, and on the 4 th day after virus attack, all ducks are subjected to section examination and virus titration of viscera. Section inspection display, 10 2.0 TCID 50 After the dose immunization group attacks the toxin, 3/10 spleen still has a certain swelling and bleeding phenomenon. And 10 (10) 2.5 TCID 50 And 10 (V) 3.0 TCID 50 No obvious visceral lesions appear after the dose immunization of the group ducks attacks the toxin. Titration results of viruses in different organs show that after virus attack, the method is carried out at 10 3.0 TCID 50 And 10 (V) 2.5 TCID 50 No virus could be detected in the viscera of the dose immunized duck, but 10 2.0 TCID 50 Virus still exists in the spleen of 3/10 ducks of the dose immunization group. Description of the results above 10 2.5 TCID 50 The NDRV strain JS01-105P can provide complete protection. Determination of minimum immunization dose of 10 for NDRV passage virus JS01-105P strain 2.5 TCID 50
EXAMPLE 4 preparation and testing of novel reovirus attenuated live vaccines
In a sterile safety cabinet, adding the virus liquid amplified by NDRV JS01-105P, 110P and 115P for 3 generations into a freeze-drying protective agent in a ratio of 9:1, mixing uniformly, quantitatively split charging into sterile ampoule bottles, freeze-drying in a freeze dryer in vacuum, capping after the freeze drying, and preserving in a refrigerator below-15 ℃ to obtain a vaccine finished product shown in figure 3.
And (3) checking a vaccine finished product: the freeze-dried vaccine is subjected to character inspection, the character of the vaccine is spongy loose lumps, the vaccine is easy to separate from the wall of a vaccine bottle, and the vaccine is quickly dissolved after diluent is added; the sterility test, mycoplasma, exogenous virus, residual water and vacuum test are carried out according to the annex of the current Chinese animal pharmacopoeia. And (3) identification and inspection: epidemic disease to be preparedDiluting the virus maintenance solution for seedling to 100TCID 50 0.1ml, equal volume and NDRV hyperimmune serum inactivated at 56 ℃ for 30min (neutralization titer not less than 1:10), 96 well cell culture plates of LMH cells well grown were inoculated after neutralization at 37 ℃ for 1h, 10 wells per batch of vaccine, 200 ul/well, while normal control cells and virus control wells were established, 10 wells each. Placing at 37deg.C 5% CO 2 Is cultured in a cell culture box for 7 days, and cytopathic conditions are observed and recorded. Normal maintenance fluid cell pores and neutralization pores should be free of cytopathic effects, and virus control pores should be cytopathic; the vaccine virus content was tested using LMH cells: randomly extracting one bottle of prepared vaccine per batch, diluting the vaccine with virus maintenance solution to 0.1ml containing 1 part according to the marked vaccine part, diluting with dilution solution by 10 times, and collecting 10 -2 、10 -3 、10 -4 、10 -5 4 dilutions, each followed by 4 replicates inoculated in 96 well plates of well grown LMH cells, 0.1mL per well, 37℃and 5% CO 2 Culturing in a cell incubator for 7 days, observing and recording cytopathic effect, and calculating the virus content TCID according to Reed-Muench method 50 The virus content of each feather should be more than or equal to 10 3.5 TCID 50
3 batches of laboratory test-prepared freeze-dried NDRV JS01-105P attenuated vaccine have good freeze-drying effect. And (3) the finished product inspection result shows that: the freeze-dried property is spongy loose agglomerate which is easy to separate from the wall of the vaccine bottle, and the diluent is added for quick dissolution; the sterility test, mycoplasma test and exogenous virus test are carried out according to the annex of the current Chinese animal pharmacopoeia, and 3 batches of vaccine have no bacteria, mycoplasma growth and exogenous virus pollution. The identification test results show that the virus control holes all generate cytopathy, and the neutralization holes and the maintenance liquid control holes in 3 batches of vaccine samples have no cytopathy.
Example 5 evaluation of safety of novel reovirus attenuated live vaccines
After the novel duck reovirus attenuated vaccine JS01-105P strain is inoculated into 1-day-old healthy susceptible duckling in single dose, single dose repetition and overdose, obvious adverse reactions are not seen at the inoculated part and the whole body, and the inoculated duckling is normal in feeding, drinking water, excretion and mental state and has no clinical reactions and pathological changes (see tables 1-3).
TABLE 1 safety test of novel reovirus attenuated vaccine JS01-105P strain single dose 1-inoculation of 1 day old duckling
TABLE 2 safety test of novel reovirus attenuated vaccine JS01-105P strain single dose repeated vaccination of 1 day old ducklings
TABLE 3 safety test of novel reovirus attenuated vaccine JS01-105P strain overdose inoculation of 1-day-old ducklings
EXAMPLE 6 evaluation of the effectiveness of novel attenuated live reovirus vaccines
Novel reovirus attenuated live vaccine JS01-105P strain is inoculated to 1-day-old duckling virus attack protection condition: (1) The clinical manifestations are that 1 day old duckling is immunized with 3 batches of NDRV JS01-105P strain vaccine, 7 days old duckling is subjected to virus attack, the vaccinated duckling group has no abnormal manifestation, and the contrast of the duckling group is characterized by reduced feed intake and diarrhea; (2) pathological changes: killing after 4 days of virus attack, checking pathological changes of immune ducks, wherein each viscera of duckling in each immune group has no obvious pathological changes, and spleen of duckling in the contrast virus attack group has different degrees of significance and necrosis, and other viscera have no obvious macroscopic lesions; (3) virus isolation: the animals were dissected 4 days after challenge, and heart, liver, spleen, lung, kidney, etc. organs of vaccinated ducklings were collected and virus isolated using LMH cells, which showed that no virus was isolated from 3 vaccine immunized ducklings, but no virus was isolated from the spleen of the control challenge group (table 4).
Table 4 effectiveness test of novel reovirus attenuated live vaccine JS01-105P strain
The foregoing examples merely illustrate embodiments of the invention and are described in more detail and are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Sequence list
<110> Shanghai veterinary institute of agricultural sciences of China (center for sea division of China center for animal health and epidemiology)
<120> novel duck reovirus attenuated strain and application thereof
<160> 6
<170> PatentIn version 3.3
<210> 1
<211> 321
<212> PRT
<213> novel Duck reovirus (Novel duck reovirus) attenuated strain JS01-105P
<400> 1
Met Asp Arg Asn Glu Val Ile Arg Leu Ile Leu Ser Leu Leu Pro Tyr
1 5 10 15
Gln Ser Ser Asp Val Asp His Leu Thr Thr Gln Ile Lys Ser Leu Gln
20 25 30
Ser Ala Val Asp Ser Leu Lys Glu Ser Gln Val Val Val Leu Arg Arg
35 40 45
Leu Thr Thr Ile Thr Ser Thr Val Ala Asp Leu Gln Ser Thr Thr Glu
50 55 60
Leu Leu Thr Ser Gln Val Ala Gly Leu Ser Ser Arg Val Ala Ser Val
65 70 75 80
Thr Asp Glu Val Val Arg Val Asn Ser Val Ile Gly Thr Thr Ile Thr
85 90 95
Asn Leu Asp Asn Val Arg Ser Glu Leu Ser Ser Leu Ser Ser Gln Val
100 105 110
Ser Ser Gln Thr Ser Thr Leu Pro Asn Leu Thr Ser Thr Val Ser Ser
115 120 125
Gln Ser Leu Ala Ile Ser Asp Leu Gln Arg Arg Val Thr Ala Leu Glu
130 135 140
Arg Ser Gly Gly Ala Pro Thr Gln Phe Glu Ala Pro Leu His Leu Gln
145 150 155 160
Asn Gly Val Val Ser Leu Gln Ala Ser Pro Ser Phe Cys Ser Leu Ser
165 170 175
Pro Ile Leu Ser Gly Pro Ala Asp Ala Ala Val Phe Lys Val Gly Glu
180 185 190
Trp Leu Gly Thr Val Ile Ser Gly Gln Ser Gln Ser Ser Ala Ile Met
195 200 205
Asn Val Arg Ile His Ser Phe Gly Gln Arg Thr Met Leu Leu Met Ser
210 215 220
Ser Gln Asn Val Phe Thr Ile Pro Pro Gly Ser Gly Ala Ser Leu Gln
225 230 235 240
Leu Asp Val Asn Arg Ile Thr Thr Pro Ala Ile Asp Ala Ala Met Val
245 250 255
Thr Pro Ser Ala Ala Phe Ala Ser Ala Ser Phe Met Ala Asp Ile Ala
260 265 270
Phe Lys Asp Ser Lys Thr Gly Glu Val His Ala Leu His Thr Thr Gly
275 280 285
Ser Phe Arg Ser Pro Ser Phe Ser Ile Val Trp Val Pro Val Ala Ser
290 295 300
Glu Thr Arg Asn Tyr Gln Ile Met Ala Leu Arg Phe Thr Val Ala Thr
305 310 315 320
Gly
<210> 2
<211> 416
<212> PRT
<213> novel Duck reovirus (Novel duck reovirus) attenuated strain JS01-105P
<400> 2
Met Ala Arg Ala Val Tyr Asp Phe Leu Ser Thr Pro Phe Gly Asn Arg
1 5 10 15
Gly Leu Ala Thr Asn Arg Thr Gln Leu Ser Ser Leu Leu Ser Ser Ser
20 25 30
Asn Ser Pro Trp Gln Arg Phe Leu Ser Ala Leu Pro Pro Leu Thr Ala
35 40 45
Pro Gly Ile Val Ser Thr Pro Glu Ala Pro Tyr Pro Gly Ser Ser Leu
50 55 60
Tyr Gln Glu Ser Met Leu His Ser Ala Thr Ile Pro Gly Ile Leu Gly
65 70 75 80
Asn Arg Asp Ala Trp Arg Asn Phe Asn Val Phe Gly Phe Ser Trp Thr
85 90 95
Asp Glu Gly Leu Ser Gly Leu Val Ala Ala Gln Asp Pro Pro Pro Ala
100 105 110
Pro Pro Tyr Gln Pro Ala Ser Gly Gln Trp Ser Asp Leu Leu Gln Tyr
115 120 125
Pro Arg Trp Ala Asn Arg Gln Arg Glu Leu Gln Ser Lys Tyr Pro Ile
130 135 140
Leu Leu Arg Ser Thr Leu Leu Ser Ala Met Arg Ala Gly Pro Val Leu
145 150 155 160
Tyr Val Glu Thr Trp Pro Asn Thr Ile Ser Gly Arg Leu Ala Asp Trp
165 170 175
Phe Met Ser Gln Tyr Gly Asn Asn Phe Val Asp Met Cys Ala Arg Leu
180 185 190
Thr Gln Ser Cys Met Asn Met Pro Val Glu Pro Asp Gly Asn Tyr Asp
195 200 205
Gln Gln Met Arg Ala Leu Ile Ser Leu Trp Leu Leu Ser Tyr Ile Gly
210 215 220
Val Val Asn Gln Ser Asn Thr Ile Asn Gly Phe Tyr Phe Ala Ser Lys
225 230 235 240
Thr Arg Gly Gln Ala Met Asp Asn Trp Thr Leu Phe Tyr Ala Thr Asn
245 250 255
Thr Asn Arg Val Gln Ile Thr Gln Arg His Phe Ala Tyr Val Cys Ala
260 265 270
Arg Ser Pro Asp Trp Asn Val Asp Lys Ser Trp Ile Ser Ala Ala Asn
275 280 285
Leu Thr Ala Ile Val Met Ala Cys Arg Gln Pro Pro Ala Phe Ala Asn
290 295 300
Gln Gly Val Ile Asn Gln Ala Gln Asn Arg Pro Gly Phe Ser Met Asn
305 310 315 320
Gly Gly Thr Pro Val His Glu Leu Asn Met Leu Thr Thr Ala Gln Ala
325 330 335
Cys Ile Gln Gln Trp Val Val Ala Asp Leu Ile Ser Ala Ala Lys Gly
340 345 350
Gln Ser Met Thr Gln Glu Ala Asn Asp Phe Ser Asn Leu Ile Gln Ala
355 360 365
Asp Leu Gly Arg Ile Lys Ala Gln Asp Asp Ala Leu Tyr Asn Gln Gln
370 375 380
Pro Gly Tyr Ala Arg Arg Ile Lys Pro Phe Ala Asn Gly Asp Trp Thr
385 390 395 400
Pro Gly Met Thr Ala Gln Ala Leu Ala Leu Leu Ala Thr Phe Thr Val
405 410 415
<210> 3
<211> 367
<212> PRT
<213> novel Duck reovirus (Novel duck reovirus) attenuated strain JS01-105P
<400> 3
Met Glu Val Arg Val Pro Asn Phe His Ser Phe Ile Glu Gly Ile Thr
1 5 10 15
Thr Ser Tyr Leu Cys Ser Pro Ala Ser Trp Asn Ser Lys Thr Leu Trp
20 25 30
Asp Ile Glu Glu Phe His Thr Pro Asp Val Ile Arg Val Gly Asn Ala
35 40 45
Tyr Cys Cys Thr Gln Cys Cys Gly Val Leu Tyr Tyr Gly Ala Pro Pro
50 55 60
Ser Asp Gly Asn Cys Phe Pro His His Lys Cys His Gln Gln Gln Tyr
65 70 75 80
Arg Thr Glu Thr Pro Leu Met Arg Tyr Ile Lys Val Gly Arg Thr Thr
85 90 95
Glu Gln Leu Leu Asp Gln Tyr Ala Ile Ala Leu His Val Ile Ala Asp
100 105 110
Tyr Tyr Asp Glu Ala Ser Lys Gln Pro His Asp Ile Ala Glu Thr Glu
115 120 125
Ser Ile Ala Pro Phe Asp Ile Val Thr Arg Thr Glu Ser Ile Arg Ser
130 135 140
Asp Arg Ala Val Asp Pro Glu Phe Trp Thr Tyr Pro Leu Glu Arg Arg
145 150 155 160
Gly Tyr Asp Ala Arg His Glu Ile Ala Arg Ala Gly Trp Lys Met Ile
165 170 175
Asp Ala Ser Ser Arg Ser His Thr Leu Pro Glu Cys Leu Val Ser Asn
180 185 190
Met Leu His Thr Arg His Val Phe Ser Gln Met Leu Thr Thr Thr Thr
195 200 205
Ile Tyr Asp Val Ala Val Thr Gly Lys Ala Val Thr Phe Ser Pro Met
210 215 220
Val Ala Thr Met Pro Thr Arg Gly Asp Gly Ala Val Ala Leu Ser Arg
225 230 235 240
Gly Asn Leu Asp His Asp Val Glu Asp Cys Trp Met Asp Gly Phe Ala
245 250 255
Phe Ser Pro Phe Ile Gly Gly Val Gly Ile Thr Gly Gln Phe Glu Arg
260 265 270
Gly Ser Cys His Asn Phe Gly His Pro Met Ile Gly Ser Gly Lys Lys
275 280 285
Ala Ser His Tyr Arg Asn Leu Phe Met Glu Ser Trp Arg Gly Trp Ser
290 295 300
Lys Ser Cys Phe Thr Cys Ala Val Gly Met Glu Pro Ala Glu Cys Glu
305 310 315 320
Ser Arg Leu Arg Gly His Ala Arg Thr Met Phe Gly Arg Ser Leu Pro
325 330 335
Asp Ile Cys Asp Phe Glu Glu Thr Thr His Ile Gly Gln Ser Ser Ala
340 345 350
Pro Leu Lys Lys Ala Thr Lys Leu Ser Phe Leu Glu Cys Arg Trp
355 360 365
<210> 4
<211> 966
<212> DNA
<213> novel Duck reovirus (Novel duck reovirus) attenuated strain JS01-105P
<400> 4
atggatcgca acgaggtgat acgcctgata ctttccctcc tcccctacca gtcaagcgac 60
gtcgatcatt tgacgacaca gatcaaatcc ctccaaagcg ccgtcgactc actgaaagaa 120
tcacaagtgg tagtcttgag acgcctgact acgattacgt cgacggtggc ggatctacaa 180
tcaacaactg aattgttgac ctcacaggtg gcaggactta gttcccgtgt ggcttcagtg 240
actgatgagg tagtccgtgt aaattcagtg attggaacta cgatcactaa tcttgacaat 300
gtccggtccg agctatcctc tctctcctcc caagtctcgt cgcagacgtc cactctaccg 360
aatcttacat caaccgtttc atcccagtct cttgcgattt ctgatctcca gcgacgagtt 420
acggccttag aacgatcggg tggtgcgccg acacaatttg aagctccctt gcacctacaa 480
aacggagtcg tctcactcca agcatctccc tctttctgtt ctttgtctcc gatcctctcc 540
ggacctgctg atgctgctgt tttcaaggtt ggtgagtggc tgggaactgt catatctggt 600
caaagtcagt catctgcaat catgaacgtg cggattcatt catttgggca gcggaccatg 660
ttgcttatgt cttcgcaaaa tgtattcact attccgccag gttcgggtgc gtctttgcag 720
ctagatgtga atcgtataac gacccctgcc attgacgctg ctatggtaac tccttccgct 780
gcttttgctt ctgcttcctt tatggctgac atagctttca aagactctaa gacaggagaa 840
gtccatgctt tacacactac tggctctttt cgatcacctt ctttctctat cgtttgggtc 900
ccggttgctt cggaaactcg taattaccaa ataatggcgt tacgcttcac cgtcgccacg 960
ggctag 966
<210> 5
<211> 1251
<212> DNA
<213> novel Duck reovirus (Novel duck reovirus) attenuated strain JS01-105P
<400> 5
atggcgcgtg ccgtgtacga ttttttatct acgcctttcg gtaaccgtgg tctggcaact 60
aaccgtactc aactgtcgtc actactgtca agttcaaatt cgccatggca acgctttttg 120
tccgccttac ctccactgac cgctccaggc attgtttcaa cccctgaggc accctacccg 180
ggttcatcgt tataccagga gtccatgctc cacagcgcta ctatccctgg gattctaggt 240
aatagagacg cgtggcgcaa tttcaacgtc ttcggctttt catggacaga tgaaggtttg 300
tcaggacttg tcgctgccca agaccctcct ccagctccac cgtaccaacc agcttcggga 360
cagtggtctg atctgcttca gtatcctcga tgggctaatc gtcaacgtga gttgcagtct 420
aaatatccta ttctgttgcg atctactttg ctttcagcta tgcgcgctgg accggtgttg 480
tacgttgaga cttggcccaa cacgatttct ggtcgacttg ctgactggtt catgtcgcag 540
tatgggaaca acttcgttga catgtgtgca cgattaactc agtcctgcat gaacatgcca 600
gttgagccgg atggtaatta tgaccagcag atgcgagcat taattagtct gtggctcctc 660
tcgtatattg gcgttgtgaa tcaatctaac actattaacg gcttctactt tgcttccaag 720
acgcgggggc aggctatgga taactggacg ctgttctatg ctaccaacac caatcgggtg 780
cagattactc agcgccactt tgcctacgtt tgcgctcgct cccccgactg gaatgtcgat 840
aagtcctgga tcagcgctgc caatttgact gccattgtca tggcttgccg ccagccgcca 900
gcctttgcca accagggggt aatcaaccag gcccagaatc gacctggatt ctcgatgaat 960
ggtggaacgc ctgtgcacga gctgaacatg ctgactaccg ctcaagcttg tatccagcag 1020
tgggtcgtag ctgatttgat ctcagcagct aagggtcagt ccatgacgca ggaggcgaat 1080
gacttctcga acctcatcca agccgatctt gggcggatca aagcgcaaga tgacgcgttg 1140
tacaaccaac aacctggtta cgctcgtcgc attaagccgt ttgccaacgg agattggact 1200
cctggaatga ctgcgcaagc attagctcta ctagccactt ttactgtcta g 1251
<210> 6
<211> 1104
<212> DNA
<213> novel Duck reovirus (Novel duck reovirus) attenuated strain JS01-105P
<400> 6
atggaggtgc gtgtgccaaa ctttcactcc tttatcgagg gtattactac tagttacttg 60
tgttctcctg cgagctggaa ttcgaagacg ttatgggata ttgaagaatt tcacacacct 120
gacgttatca gggtcggcaa tgcttattgt tgcactcagt gctgtggtgt tctgtactat 180
ggtgcccctc cctctgatgg aaactgtttt ccacatcaca agtgtcatca acagcaatat 240
cgtactgaga ctccgctcat gagatatatt aaggtgggtc gcactacaga gcaactgctt 300
gatcaatatg ccattgctct gcatgtcatt gcagattact atgacgaggc gagtaagcaa 360
cctcatgata tcgctgaaac tgagtcaatc gcaccatttg atatcgtaac caggactgaa 420
tctattcgca gtgaccgtgc cgttgacccg gaattctgga cttatccgtt agagagacga 480
ggatacgacg cgcgacatga gattgctaga gcgggttgga agatgatcga tgcttcatcg 540
cgaagtcaca ctcttcctga atgtctggtg tcaaatatgc tacatactag acatgtcttc 600
agccaaatgt tgaccacgac aaccatctat gatgtcgctg tcacgggtaa agctgttaca 660
ttcagcccga tggtagcaac catgccaact cgaggagatg gtgctgtggc tctgtcaaga 720
ggtaacttgg atcatgatgt cgaggactgt tggatggatg gttttgcatt ctcccccttc 780
atcggcggtg ttggcatcac tggtcaattt gagcgtggct cctgccataa ttttggacac 840
cccatgattg gaagcggtaa gaaggcttct cactaccgca atttattcat ggaatcctgg 900
cgtggatggt caaagtcgtg ctttacatgt gctgtaggga tggagcccgc ggagtgcgaa 960
tctaggctgc gaggccatgc cagaactatg ttcggacgtt ctcttccgga tatctgtgac 1020
ttcgaggaga ctacccacat tggccagtcg tccgcgccct taaagaaggc cacgaaattg 1080
tccttcctgg agtgtaggtg gtaa 1104

Claims (4)

1. A novel duck reovirus attenuated strain with a preservation number of CCTCC NO: v202168.
2. A vaccine comprising the novel duck reovirus attenuated strain of claim 1.
3. The vaccine of claim 2, wherein the virus content per feather of the vaccine is not less than 10 3.5 TCID 50
4. Use of a novel duck reovirus attenuated strain of claim 1 in the preparation of a product for preventing a novel duck reovirus disease.
CN202111076984.8A 2021-09-14 2021-09-14 Novel duck reovirus attenuated strain and application thereof Active CN113832113B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111076984.8A CN113832113B (en) 2021-09-14 2021-09-14 Novel duck reovirus attenuated strain and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111076984.8A CN113832113B (en) 2021-09-14 2021-09-14 Novel duck reovirus attenuated strain and application thereof

Publications (2)

Publication Number Publication Date
CN113832113A CN113832113A (en) 2021-12-24
CN113832113B true CN113832113B (en) 2023-09-22

Family

ID=78959246

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111076984.8A Active CN113832113B (en) 2021-09-14 2021-09-14 Novel duck reovirus attenuated strain and application thereof

Country Status (1)

Country Link
CN (1) CN113832113B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114958781B (en) * 2022-07-28 2022-11-11 佛山科学技术学院 NDRV low virulent strain and breeding method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102352346A (en) * 2011-10-24 2012-02-15 福建省农业科学院畜牧兽医研究所 Novel-pathotype duck reovirus and attenuated vaccine thereof
CN104711240A (en) * 2015-03-18 2015-06-17 广西壮族自治区兽医研究所 Application of sigma A protein of avian reovirus and related biological materials of sigma A protein
CN109295007A (en) * 2018-09-19 2019-02-01 福建省农业科学院畜牧兽医研究所 The selection of NDRV low virulent strain and its preparing the application in NDRV live vaccine
CN111172122A (en) * 2020-01-07 2020-05-19 齐鲁动物保健品有限公司 Duck reovirus attenuated strain and application thereof
CN111440815A (en) * 2020-03-12 2020-07-24 潍坊华英生物科技有限公司 Novel duck reovirus composite vaccine and preparation method of yolk antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273287B2 (en) * 2008-06-26 2016-03-01 Biomune Company Avian reoviridae and vaccines thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102352346A (en) * 2011-10-24 2012-02-15 福建省农业科学院畜牧兽医研究所 Novel-pathotype duck reovirus and attenuated vaccine thereof
CN104711240A (en) * 2015-03-18 2015-06-17 广西壮族自治区兽医研究所 Application of sigma A protein of avian reovirus and related biological materials of sigma A protein
CN109295007A (en) * 2018-09-19 2019-02-01 福建省农业科学院畜牧兽医研究所 The selection of NDRV low virulent strain and its preparing the application in NDRV live vaccine
CN111172122A (en) * 2020-01-07 2020-05-19 齐鲁动物保健品有限公司 Duck reovirus attenuated strain and application thereof
CN111440815A (en) * 2020-03-12 2020-07-24 潍坊华英生物科技有限公司 Novel duck reovirus composite vaccine and preparation method of yolk antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Isolation and characterization of a naturally attenuated novel duck reovirus strain as a live vaccine candidate;Hui Yan等;Veterinary Microbiology;第261卷;1-10 *
新型鸭呼肠孤病毒病浓缩灭活疫苗的制备及免疫原性分析;陈仕龙等;福建农业学报(11);21-24 *

Also Published As

Publication number Publication date
CN113832113A (en) 2021-12-24

Similar Documents

Publication Publication Date Title
CN104862286B (en) Porcine pseudorabies virus gene-deleted strain, vaccine composition and its preparation method and application
CN104513827A (en) Porcine epizootic diarrhea virus strain, attenuated vaccine strain thereof and application thereof
CN104498441B (en) Duck hepatitis A virus (HAV) type III low virulent strain and live vaccine prepared therefrom and application
CN106282130A (en) A kind of I group 4 type aviadenovirus, inactivated vaccine and preparation method thereof
CN113491767A (en) Triple inactivated vaccine for duck circovirus disease, novel duck reovirus disease and duck viral hepatitis and preparation method thereof
CN113832113B (en) Novel duck reovirus attenuated strain and application thereof
CN111154730A (en) Goose astrovirus variant strain
CN108465107B (en) Duck type 2 adenovirus and Muscovy duck parvovirus disease combined inactivated vaccine
CN112280750B (en) Novel goose astrovirus with cross-species transmission capability and application thereof
CN105802920A (en) Infectious bursal disease virus strain A11 and application thereof
CN101235363B (en) Pig transmissible gastroenteritis virus vaccine strain and application thereof
CN112538464A (en) Reverse genetic vaccine strain rHN20 of avian adenovirus serotype 4 as well as construction method and application thereof
CN105802918B (en) Chicken&#39;s infectious bronchitis nephritis strain and its vaccine composition, preparation method and application
CN104130981A (en) Application of avian infectious bronchitis virus vaccine strain in preparation of inactivated vaccine
CN109797139B (en) 3-type duck hepatitis A virus attenuated strain CH-P60 and application thereof
KR101102271B1 (en) Attenuated Avian Infectious Bronchitis Virus and Vaccine for Avian Infectious Bronchitis Comprising the Same
CN103937817A (en) Newcastle disease virus YT strain as well as whole genome sequence and application thereof
CN114891753B (en) Novel duck reovirus passaging attenuated strain and application thereof
CN111172122B (en) Duck reovirus attenuated strain and application thereof
CN106822888B (en) Peste des petits ruminants and goat pox combined live vaccine and production method thereof
CN109055320A (en) One plant of infectious bronchitis virus separation strains and the application in vaccine preparation
CN116286670A (en) Novel duck reovirus and application thereof in preparation of inactivated vaccine and egg yolk antibody
KR101092977B1 (en) Avian Infectious Bronchitis Virus and Vaccine for Avian Infectious Bronchitis Comprising the Same
CN104248761B (en) A kind of vaccine combination and its preparation method and application
CN110713987B (en) Recombinant gene VII type Newcastle disease virus strain and vaccine composition, preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant